BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suhas S, Kumar V, Damodharan D, Sharma P, Rao NP, Varambally S, Venkatasubramanian G, Murthy P, Gangadhar BN. Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level? Schizophr Res. 2020;222:195-201. [PMID: 32518001 DOI: 10.1016/j.schres.2020.05.057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Suhas S, Manchegowda S, Venkatasubramanian G, Kumar V. Clozapine and Oral Contraceptives-Implications Beyond Pharmacokinetics: A Case Report. J Clin Psychopharmacol 2021;41:487-90. [PMID: 34166256 DOI: 10.1097/JCP.0000000000001415] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopeček M, Švancer P, Olmos I, Vázquez M, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, de Leon J. European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed. J Clin Psychopharmacol 2021;41:140-7. [PMID: 33587398 DOI: 10.1097/JCP.0000000000001341] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Suhas S, Mehta UM. A redux of schizophrenia research in 2021. Schizophr Res 2022:S0920-9964(22)00130-X. [PMID: 35300898 DOI: 10.1016/j.schres.2022.03.003] [Reference Citation Analysis]
4 Naskar C. Understanding the effect of various factors on clozapine serum levels in Indian population. Schizophr Res 2021;231:178. [PMID: 33866263 DOI: 10.1016/j.schres.2021.04.003] [Reference Citation Analysis]
5 de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopeček M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, Las Cuevas C, Cohen D, Schulte PFJ, Ertuğrul A, Yağcıoğlu AEA, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Rădulescu FŞ, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubała WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ristic DI, Ortiz BB, Elkis H, Pacheco Palha AJ, LLerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Saffian SM, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry 2021. [PMID: 34911124 DOI: 10.1055/a-1625-6388] [Reference Citation Analysis]
6 Grover S, Kasudhan KS, Murali N, Patil AN, Pattanaik S, Chakrabarti S, Avasthi A. Pharmacometabolomics-guided clozapine therapy in treatment resistant schizophrenia: Preliminary exploration of future too near. Asian J Psychiatr 2021;67:102939. [PMID: 34844176 DOI: 10.1016/j.ajp.2021.102939] [Reference Citation Analysis]
7 Chakrabarti S. Clozapine resistant schizophrenia: Newer avenues of management. World J Psychiatr 2021; 11(8): 429-448 [PMID: 34513606 DOI: 10.5498/wjp.v11.i8.429] [Reference Citation Analysis]
8 Suhas S, Kumar V, Venkatasubramanian G. Therapeutic drug monitoring of clozapine in Indian patients with schizophrenia - Authors response. Schizophr Res 2021;229:25-6. [PMID: 33609987 DOI: 10.1016/j.schres.2021.01.022] [Reference Citation Analysis]
9 Hassab Errasoul A, Alarabi MA. Factors predicting serum clozapine levels in Middle Eastern patients: an observational study. BMC Psychiatry 2022;22. [DOI: 10.1186/s12888-022-03910-6] [Reference Citation Analysis]
10 De Las Cuevas C, Sanz EJ, Ruan CJ, de Leon J. Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries. Rev Psiquiatr Salud Ment 2021:S1888-9891(21)00070-7. [PMID: 34298164 DOI: 10.1016/j.rpsm.2021.07.004] [Reference Citation Analysis]
11 Nomura N, Kitagawa K, So R, Misawa F, Kodama M, Takeuchi H, Bies R, Straubinger T, Banker C, Mizuno Y, Mimura M, Uchida H. Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study. Ther Adv Psychopharmacol 2021;11:20451253211016189. [PMID: 34046160 DOI: 10.1177/20451253211016189] [Reference Citation Analysis]